NuCana PLC (NCNA) Stake Lifted by Woodford Investment Management Ltd
Woodford Investment Management Ltd grew its position in NuCana PLC (NASDAQ:NCNA) by 27.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 420,000 shares of the company’s stock after acquiring an additional 90,000 shares during the period. NuCana comprises 1.0% of Woodford Investment Management Ltd’s portfolio, making the stock its 8th largest holding. Woodford Investment Management Ltd owned 1.32% of NuCana worth $7,980,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. Asymmetry Capital Management L.P. lifted its holdings in shares of NuCana by 18.4% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock valued at $910,000 after buying an additional 7,424 shares during the period. Alps Advisors Inc. lifted its holdings in shares of NuCana by 8.2% during the 2nd quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock valued at $879,000 after buying an additional 3,508 shares during the period. Baillie Gifford & Co. lifted its holdings in shares of NuCana by 2.2% during the 2nd quarter. Baillie Gifford & Co. now owns 655,450 shares of the company’s stock valued at $12,454,000 after buying an additional 14,330 shares during the period. Finally, Sofinnova Ventures Inc bought a new position in shares of NuCana during the 1st quarter valued at $88,293,000. 24.42% of the stock is currently owned by institutional investors and hedge funds.
NCNA has been the topic of a number of recent research reports. Cowen reaffirmed a “buy” rating on shares of NuCana in a report on Wednesday, August 29th. Zacks Investment Research raised NuCana from a “sell” rating to a “hold” rating in a report on Wednesday, May 23rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. NuCana currently has a consensus rating of “Buy” and a consensus price target of $21.00.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.